<DOC>
	<DOCNO>NCT02275806</DOCNO>
	<brief_summary>This prospective , single institution phase II study , whose primary objective estimate median three year survival rate non-small lung cancer patient Stage IIIA IIIB intra-thoracic disease refer `` locally advanced '' non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Cisplatin/Irinotecan With Concurrent Radiation Inoperable NSCLC</brief_title>
	<detailed_description>Patients histological document non-small cell lung cancer , consider inoperable , meet eligibility criterion , sign inform consent treat one cycle irinotecan cisplatin , follow three additional cycle chemotherapy 60 - 70 Gy concurrent radiation therapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histological cytological document NSCLC , include squamous cell carcinoma , adenocarcinoma , large cell carcinoma include large cell neuroendocrine carcinoma adenosquamous sarcomatoid carcinoma . Patients Pancoast tumor adjacent vertebral body eligible long gross disease encompass radiation boost field . Pancoast tumor patient sonoted registry . Patients must ≥ 18 year age . Patients Zubrod ( ECOG ) performance status ≤ 2 . Adequate hematologic function define : ANC ≥ 1000/mm3 , platelet ≥ 75,000/mm3 , hemoglobin ≥ 8 g/dL ( prior transfusion ) ; adequate hepatic function define : total bilirubin ≤ 3.0 mg/dl , adequate renal function define serum creatinine level ≤ 2.0 mg/dl . Patients weight loss ≤ 20 % past 3 month . Patients pleural effusion proven cytologically negative small tap . Women childbearing potential must agree practice effective contraception throughout study four week completion treatment . Pretreatment evaluation require eligibility include : A medical history , physical examination , assessment Zubrod performance status within 4 week prior study entry . CBC differential platelet count , laboratory profile must complete within 4 week prior study entry . CT scan chest whole body PET ( prefer ) , CT scan MRI ( prefer ) brain within 4 week prior study entry . For woman childbearing potential , serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) must perform within week prior start protocol treatment . Medical Oncology Radiation Oncology consultation approval . Patients must sign studyspecific consent form prior study entry . Small cell carcinoma carcinoid histology . History malignancy past 2 year except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ cancer . Prior systemic chemotherapy radiotherapy would interfere delivery treatment outline judged clinician . Cytologically malignant effusion . Radiographic evidence metastatic disease . Active pulmonary infection responsive antimicrobial therapy . History significant symptomatic interstitial pneumonitis . Significant symptomatic cardiac disease , example , unstable angina , uncompensated congestive heart failure , uncontrolled cardiac ventricular arrhythmia . Patients &gt; grade 2 neuropathy . Women pregnant breast feeding , treatment involve unforeseeable risk participant , embryo , fetus , nurse infant ; woman positive pregnancy test enrollment prior study drug administration . Women childbearing potential unwilling practice effective contraception throughout study four week completion treatment . Patients currently participate clinical trial and/or participate clinical trial previous 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>